Regulation of Hematopoietic Stem Cell Processing and Transplantation

Springer Science and Business Media LLC - Tập 75 - Trang 237-245 - 2002
Scott D. Rowley1
1Hackensack University Medical Center, Hackensack, New Jersey, USA

Tóm tắt

The widespread use of tissue including hematopoietic stem cell products is justification for the development of standards by professional societies and for regulation by governmental agencies. The Food and Drug Administration (FDA) developed a tiered, risk-based regulatory model.At the low end of risk to the tissue recipient, the regulations being developed by the FDA are comparable to standards developed by the Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) and recognize a basic level of practice in the collection, processing, and distribution of hematopoietic stem cell (HSC) products. This basic level of practice, when fully enacted, will be found in part 1271 of chapter 21 of the Code of Federal Regulations (CFR), which includes criteria for facility management, quality control, donor selection, and the processing of cells. The regulatory approach adopted by the FDA is more comprehensive than FAHCT standards, however. It defines higher levels of regulatory oversight that combines appropriate sections of part 1271 with current good manufacturing practice requirements described in parts 210, 211, and 820 of chapter 21 of the CFR for HSC products that are more than minimally manipulated.

Tài liệu tham khảo

McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.Blood. 2001;97:3390–3400. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy.Ann Rev Med. 1999;50:507–529. Pecora AL. Progress in clinical application of use of progenitor cells expanded with hematopoietic growth factors.Curr Opin Hematol. 2001;8:142–148. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.Blood. 1998;2:1549–1555. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraft-ment and survival in adult recipients of umbilical-cord blood from unrelated donors.N Engl J Med. 2001;344:1815–1822. Human tissue intended for transplantation, 58Federal Register 65514 (1993). Human Tissue Intended for Transplantation, 62Federal Register 40429 (1997). A proposed approach to the regulation of cellular and tissue-based products, 62Federal Register 9721 (1997). Kessler DA, Siegel JP, Noguchi PD, et al. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration.N Engl J Med. 1993;329:1169–1173. Application of current statutory authorities to human somatic cell therapy products and gene therapy products, 58Federal Register 53248 (1993). Draft document concerning the regulation of placental/umbilical cord blood stem cell products intended for transplantation or further manufacture into injectable products, [availability], 61Federal Register 7087 (1996). Food and Drug Administration.Guidance for Human Somatic Cell Therapy and Gene Therapy. Rockville, Md: National Press Office: March, 1998. Human cells, tissues, and cellular and tissue-based products; establishment registration and listing [final rule], 66Federal Register 5447 (2001). CFR 600.11(e)(3), 1998. CFR 600.11(e)(4), 1998. Food and Drug Administration.Guidance for the submission of chemistry, manufacturing, and controls information and establishment description for autologous somatic cell therapy products. Docket 95N-0200: Part 2.B.2. (1997). Food and Drug Administration.Guidance for the submission of chemistry, manufacturing, and controls information and establishment description for autologous somatic cell therapy products. Docket 95N-0200: Part 2.B.3. (1997). CFR 211.28(d), 1998. CFR 600.10(c)(4), 1998. CFR 211.84(b), 1998. CFR 211.100(b), 1998. The Food and Drug Administration’s development, issuance, and use of guidance documents. 62Federal Register 8961 (1997). Standards for Hematopoietic Progenitor Cell Collection, Processing & Transplantation, First Edition. Omaha, Neb: Foundation for the Accreditation of Hematopoietic Cell Therapy; 1996. Request for proposed standards for unrelated allogeneic peripheral and placental/umbilical cord blood hematopoietic stem/progenitor cell products; request for comments. 63Federal Register 2985 (1998).